Literature DB >> 25279148

Co-culture of hepatocellular carcinoma cells and human umbilical endothelial cells damaged by SU11274.

Minoru Tomizawa1, Fuminobu Shinozaki2, Yasufumi Motoyoshi3, Takao Sugiyama4, Shigenori Yamamoto5, Naoki Ishige6.   

Abstract

Mesenchymal-epithelial transition factor (c-Met) is a receptor that binds to the hepatocyte growth factor and is upregulated in hepatocellular carcinoma (HCC). The anti-tumor effects of (3Z)-N-(3-chlorophenyl)-3-({3,5-dimethyl-4-[(4- methyl-piperazin-1-yl)carbonyl]-1H-pyrrol-2-yl}methylene)-N-me- thyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide (SU11274), a c-Met inhibitor, were investigated in the present study. HCC cells (HLE, HLF, PLC/PRL/5, Hep3B, Huh-6 and HepG2) and human umbilical vein endothelial cells (HUVECs) were used. Quantitative polymerase chain reaction was performed to detect the expression level of c-Met in HCC and HUVECs, and cyclin D1 in HCC. The 3-(4,5-dimethylthiazol-2-yl)-5-(3-car-boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt assay was performed to assess the proliferation of the HCC cells and HUVECs cultured with SU11274. Co-culture of HLF or PLC/PRL/5 cells and HUVECs was established as an in vitro model of HCC tissues. The expression levels of c-Met in HLE, HLF, PLC/PRL/5, Hep3B, Huh-6 and HepG2, adult healthy liver and HUVECs were 4.43±0.50, 1.61±0.18, 3.70±0.08, 0.81±0.18, 6.60±1.29, 1.06±0.35, 1.00±0.09 and 88.8±17.3 (mean ± standard deviation), respectively. SU11274 (30 μM) suppressed the proliferation of HLF, PLC/PRL/5 and HUVECs to 11.0±9.4, 46.5±30.7 and 29.4±5.0%, respectively. SU11274 (30 μM) decreased the expression levels of cyclin D1 in HLF and PLC/PRL/5 cells to 45.1±11.6 and 30.1±10.3%, respectively. SU11274, at a concentration of 30 μM damaged the morphology of the co-cultures of HLF or PLC/PRL/5 cells with HUVECs and all the cells died. c-Met is highly expressed in HUVECs and HCC cells, but not in Hep3B. At a 30-μM concentration, SU11274 suppresses the proliferation of HLF, PLC/PRL/5 and HUVECs. SU11274 (30 μM) damages the co-cultures of HLF or PLC/PRL/5 cells with HUVECs.

Entities:  

Keywords:  mesenchymal-epithelial transition factor; quantitative polymerase reaction

Year:  2014        PMID: 25279148      PMCID: PMC4179721          DOI: 10.3892/br.2014.361

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  19 in total

1.  Insulin-like growth factor I receptor involvement in proliferation of NOR-P1 cells in serum-free media.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Takao Sugiyama; Shigenori Yamamoto; Makoto Sueishi; Takanobu Yoshida
Journal:  J Cell Biochem       Date:  2012-08       Impact factor: 4.429

Review 2.  Sorafenib for treatment of hepatocellular carcinoma: a systematic review.

Authors:  Bingru Xie; David H Wang; Stuart Jon Spechler
Journal:  Dig Dis Sci       Date:  2012-03-27       Impact factor: 3.199

Review 3.  Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future.

Authors:  Hwi Young Kim; Joong-Won Park
Journal:  Liver Cancer       Date:  2014-03       Impact factor: 11.740

4.  Growth patterns and interstitial invasion of small hepatocellular carcinoma.

Authors:  M Tomizawa; F Kondo; Y Kondo
Journal:  Pathol Int       Date:  1995-05       Impact factor: 2.534

5.  Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.

Authors:  Junji Furuse; Hiroshi Ishii; Kohei Nakachi; Eiichiro Suzuki; Satoshi Shimizu; Keiko Nakajima
Journal:  Cancer Sci       Date:  2007-10-22       Impact factor: 6.716

6.  Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions.

Authors:  W F Grigioni; M Fiorentino; A D'Errico; A Ponzetto; T Crepaldi; M Prat; P M Comoglio
Journal:  Hepatology       Date:  1995-06       Impact factor: 17.425

7.  Hepatocyte growth factor protects endothelial cells against gamma ray irradiation-induced damage.

Authors:  Shun-Ying Hu; Hai-Feng Duan; Qing-Fang Li; Yue-Feng Yang; Jin-Long Chen; Li-Sheng Wang; Hua Wang
Journal:  Acta Pharmacol Sin       Date:  2009-09-14       Impact factor: 6.150

8.  c-Met inhibitors.

Authors:  Anum Mughal; Hafiz Muhammad Aslam; Asfandyar Sheikh; Agha Muhammad Hammad Khan; Shafaq Saleem
Journal:  Infect Agent Cancer       Date:  2013-04-08       Impact factor: 2.965

9.  Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.

Authors:  Hao Hu; Zhenhua Duan; Xiaoran Long; Yancu Hertzanu; Haibin Shi; Sheng Liu; Zhengqiang Yang
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

10.  Niclosamide suppresses Hepatoma cell proliferation via the Wnt pathway.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Makoto Sueishi; Takanobu Yoshida
Journal:  Onco Targets Ther       Date:  2013-11-18       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.